ORL; journal for oto-rhino-laryngology and its related specialties · 2020
Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumai Takumi, Komatsuda Hiroki, Minami Yoshinori, Harabuchi Yasuaki
Аннотация
The effect of PD-1 blockade as a first-line therapy in nonmetastatic head and neck squamous cell carcinoma (HNSCC) remains unknown. We report a case of an exceptional response to PD-1 blockade as a first-line therapy in a patient with HNSCC and lung cancer. A 59-year-old man presented with cheek swelling and chest pain. He was diagnosed with maxillary sinus carcinoma (squamous cell carcinoma) and lung cancer (non-small-cell lung cancer, not otherwise specified). The maxillary sinus carcinoma was completely resolved after 8 cycles of pembrolizumab. Immune checkpoint blockade warrants further evaluation in previously untreated patients with HNSCC.
Предметные рубрики MeSH
Antibodies, Monoclonal, HumanizedAntigens, NeoplasmAntineoplastic Agents, ImmunologicalBiomarkers, TumorCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsHumansMaleMaxillary SinusMiddle AgedPositron Emission Tomography Computed TomographyProgrammed Cell Death 1 ReceptorSquamous Cell Carcinoma of Head and NeckTomography Scanners, X-Ray ComputedTreatment Outcome